Perceptive Advisors LLC Purchases New Position in Phathom Pharmaceuticals, Inc. $PHAT

Perceptive Advisors LLC acquired a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 925,000 shares of the company’s stock, valued at approximately $10,277,000.

Other institutional investors have also recently bought and sold shares of the company. Hussman Strategic Advisors Inc. acquired a new stake in Phathom Pharmaceuticals in the fourth quarter worth $2,439,000. SummitTX Capital L.P. boosted its position in shares of Phathom Pharmaceuticals by 92.3% during the first quarter. SummitTX Capital L.P. now owns 995,885 shares of the company’s stock worth $11,064,000 after purchasing an additional 478,065 shares in the last quarter. Next Century Growth Investors LLC bought a new position in shares of Phathom Pharmaceuticals during the fourth quarter worth $6,533,000. EcoR1 Capital LLC acquired a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at $6,944,000. Finally, Stratos Wealth Partners LTD. acquired a new position in shares of Phathom Pharmaceuticals in the 4th quarter valued at $834,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday. Needham & Company LLC decreased their target price on Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Friday, July 17th. Craig Hallum restated a “buy” rating and issued a $20.00 price target on shares of Phathom Pharmaceuticals in a report on Friday. Finally, Guggenheim dropped their price target on Phathom Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Phathom Pharmaceuticals Stock Down 3.1%

Phathom Pharmaceuticals stock opened at $8.75 on Friday. The stock has a market capitalization of $697.90 million, a PE ratio of -6.84 and a beta of 0.49. Phathom Pharmaceuticals, Inc. has a twelve month low of $8.02 and a twelve month high of $18.31. The company has a 50 day moving average of $10.77 and a 200-day moving average of $11.70.

Key Stories Impacting Phathom Pharmaceuticals

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Phathom reported second-quarter revenue of approximately $74.3 million, ahead of the $72.7 million analyst consensus. Earnings also improved substantially from the year-earlier period, with some reports characterizing results as breakeven, although another data source reported a loss of $0.08 per share versus expectations for a $0.06 loss. Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Needham maintained a “buy” rating and set a $22 price target, implying substantial potential upside from recent trading levels. The target, however, was reduced from $28, limiting the positive impact. Phathom Pharmaceuticals Given New Price Target at Needham
• Neutral Sentiment: Management is expanding its commercial organization to more than 290 sales representatives, indicating continued investment in product growth but also potentially increasing near-term operating costs. Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Phathom lowered its fiscal 2026 revenue guidance to $310 million-$325 million, below the roughly $334.3 million consensus estimate and below its previous high end of $345 million. The outlook reduction was the primary fundamental catalyst for the sharp decline in the stock. Phathom Pharmaceuticals Investigation Notice
• Negative Sentiment: Levi & Korsinsky announced an investigation into whether Phathom may have violated securities laws in connection with its guidance update. The potential legal overhang adds further pressure following the guidance reduction.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.